Expression of tissue inhibitor of metalloproteinase-1, -2, and -3 during neointima formation in organ cultures of human saphenous vein

被引:44
作者
Kranzhöfer, A [1 ]
Baker, AH [1 ]
George, SJ [1 ]
Newby, AC [1 ]
机构
[1] Univ Bristol, Bristol Royal Infirm, Inst Heart, Bristol BS2 8HW, Avon, England
关键词
vascular smooth muscle cells; coronary artery bypass grafting; arteriosclerosis; metalloproteinases; proliferation;
D O I
10.1161/01.ATV.19.2.255
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Degradation of the extracellular basement membrane is implicated in atherosclerosis, restenosis after angioplasty, and intimal thickening of vein grafts. Upregulation of metalloproteinase (MMP)-2 and MMP-9 accompanies neointima formation in cholesterol-fed rabbits, in rat and pig models of angioplasty, and in organ cultures of human saphenous veins. MMPs are inhibited by binding to tissue inhibitors of MMPs (TIMPs). Relatively little is known about their regulation in relationship to neointima formation; thus, we investigated TIMP expression in the organ culture model. Qualitative reverse transcriptase-polymerase chain reaction of mRNA extracted from veins showed that TIMP-1, TIMP-2, and TIMP-3 are each expressed before rind after culture. Zymography revealed that TIMP-1 was the most abundant TIMP secreted and that its secretion increased dramatically between 0 to 2 and 12 to 14 days of culture. An enzyme-linked immunosorbent assay showed that TIMP-1 secretion increased from 3.2+/-1.5 (mean+/-SE) to 32+/-6 ng/mg wet weight per day (n=5, P<0.01). Immunocytochemical testing localized the increased expression of TIMP-1 to neointimal smooth muscle cells. Although less abundant, TIMP-2 secretion also increased from 0.8+/-0.3 to 4.7+/-0.2 ng/mg wet weight per day (n=5, P<0.001), and tissue levels increased from 33+/-7 to 150+/-70 ng/mg wet weight (P<0.05). TIMP-2 was also immunolocalized to neointimal smooth muscle cells and their surrounding matrix. TIMP-3 was not secreted but was detected variably and constitutively in tissue extracts (160+/-120 and 170+/-100 ng/mg wet weight [n=9] on days 2 and 14, respectively). TIMP-3 was found in the cells and extracellular matrix of the media and adventitia before culture and to a lesser extent in the neointima after 14 days of culture. Rates of total TIMP secretion on day 14 exceeded those of MMP-2 and MMP-9 (10.6+/-1.9 and 15.6+/-2.3 ng/mg wet weight per day, respectively). Consistent with this, in situ zymography showed that MMP gelatinase activity was highly localized to cell bodies in the media and neointima. Secretion of TIMP-1 and TIMP-2 is greatly increased during neointima formation in human saphenous veins. TIMP-1 is readily released, whereas TIMP-2 remains partially attached and TIMP-3 exclusively attached to the extracellular matrix. Regulation of TIMP expression is therefore an important determinant of net MMP activity during neointima formation, restricting it to the pericellular environment.
引用
收藏
页码:255 / 265
页数:11
相关论文
共 50 条
[1]   THE FUTURE OF SAPHENOUS-VEIN AS A CORONARY-ARTERY BYPASS CONDUIT [J].
ANGELINI, GD ;
NEWBY, AC .
EUROPEAN HEART JOURNAL, 1989, 10 (03) :273-280
[2]   THE GENE STRUCTURE OF TISSUE INHIBITOR OF METALLOPROTEINASES (TIMP)-3 AND ITS INHIBITORY ACTIVITIES DEFINE THE DISTINCT TIMP GENE FAMILY [J].
APTE, SS ;
OLSEN, BR ;
MURPHY, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) :14313-14318
[3]   Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and-2 genes: Characterization of their infection into rabbit smooth muscle cells and human MCF-7 adenocarcinoma cells [J].
Baker, AH ;
Wilkinson, GWG ;
Hembry, RM ;
Murphy, G ;
Newby, AC .
MATRIX BIOLOGY, 1996, 15 (06) :383-395
[4]   Prevention of vein graft failure: potential applications for gene therapy [J].
Baker, AH ;
Mehta, D ;
George, SJ ;
Angelini, GD .
CARDIOVASCULAR RESEARCH, 1997, 35 (03) :442-450
[5]   Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury [J].
Bendeck, MP ;
Irvin, C ;
Reidy, MA .
CIRCULATION RESEARCH, 1996, 78 (01) :38-43
[6]   MATRIX METALLOPROTEINASES - A REVIEW [J].
BIRKEDALHANSEN, H ;
MOORE, WGI ;
BODDEN, MK ;
WINDSOR, LJ ;
BIRKEDALHANSEN, B ;
DECARLO, A ;
ENGLER, JA .
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 1993, 4 (02) :197-250
[7]  
CAMPEAU L, 1983, CIRCULATION, V68, P1
[8]  
CHIRGWIN J, 1979, BIOCHEMISTRY-US, V18, P5293
[9]   SEQUENCE OF HUMAN-TISSUE INHIBITOR OF METALLOPROTEINASES AND ITS IDENTITY TO ERYTHROID-POTENTIATING ACTIVITY [J].
DOCHERTY, AJP ;
LYONS, A ;
SMITH, BJ ;
WRIGHT, EM ;
STEPHENS, PE ;
HARRIS, TJR ;
MURPHY, G ;
REYNOLDS, JJ .
NATURE, 1985, 318 (6041) :66-69
[10]   INVOLVEMENT OF AP1 AND PEA3 BINDING-SITES IN THE REGULATION OF MURINE TISSUE INHIBITOR OF METALLOPROTEINASES-1 (TIMP-1) TRANSCRIPTION [J].
EDWARDS, DR ;
ROCHELEAU, H ;
SHARMA, RR ;
WILLS, AJ ;
COWIE, A ;
HASSELL, JA ;
HEATH, JK .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1171 (01) :41-55